BioCentury
ARTICLE | Clinical News

ACI-24: Phase Ib start

January 18, 2016 8:00 AM UTC

This quarter, AC Immune will begin a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate subcutaneous ACI-24 for 12 months in 24 adults with Down syndrome. The trial is funded by NIH and...